STAT+: Pharmalittle: U.S. health agency workers fail to report political interference; Canada walks back some drug-pricing reforms
And so, another working week will soon draw to a close. Not a moment too…
Category: Pharma
STAT+: Pharmalittle: U.S. spending on medicines rose 12% last year; Louisiana sues a PBM for allegedly overcharging
Top of the morning to you. And a fine one it is. Blue skies and…
STAT+: U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies
Thanks to Covid-19 vaccines and therapies, U.S. spending on pharmaceuticals rose 12% in 2021 as…
STAT+: Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions
Endo International won a key battle over its role in the opioid crisis in Tennessee…
STAT+: Louisiana accuses UnitedHealth and its OptumRx PBM of inflating drug costs for its Medicaid program
In the latest bid to pull back the curtain on pharmacy benefit managers, the Louisiana…
STAT+: Pfizer faces criticism for arguing that intellectual property for its Covid-19 pill is a human right
Numerous advocacy groups and institutional shareholders are chiding Pfizer for arguing that its intellectual property…
STAT+: Pharmalittle: Glaxo workers in the U.K. vote to strike; Alabama reaches $276 million deal over opioid crisis
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Pharmalittle: Global demand for Pfizer Covid-19 pill falls; biotech hub in Massachusetts set for a correction
Rise and shine, everyone, a busy day is on the way. We can tell thanks…
.jpg)
STAT+: Animal rights group urges USDA to probe research facilities for failing to inspect monkey shipments
A prominent animal rights group asked U.S. authorities to investigate leading medical research labs for…
STAT+: Pharmalittle: U.K watchdog agency is urged to bolster conflicts policy; FDA device program helps makers more than patients
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: WTO head says Covid vaccine IP talks are nearing agreement; RSV is the next big target for vaccine makers
And so, another working will soon draw to a close. Not a moment too soon,…
STAT+: Bristol Myers agrees to settle lawsuit alleging anti-competitive deals involving HIV drugs
After three years of squabbling, Bristol Myers Squibb has agreed to pay up to $11…
STAT+: Pharmalittle: Justice Department probes Bausch over marketing; Pfizer to seek Covid booster for healthy 5- to 11-year-olds
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Justice Department probes Bausch Health over marketing for dermatology drugs
Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines…
STAT+: Pharmalittle: U.K. advances novel payment system for antibiotics; Glaxo to pay $1.9 billion for Sierra Oncology
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: A $2.1 million price tag for Bluebird Bio’s gene therapy is cost-effective, analysis finds
As the U.S. health care system braces for expensive gene therapies, a new analysis suggests…
STAT+: Good fortunes continue for Sierra Oncology with $1.9 billion acquisition by U.K. pharma giant Glaxo
Sierra Oncology is having a very good year. On Wednesday, the small U.S. drugmaker said…
STAT+: Pharma pledges faster drug launches in Europe in hopes of avoiding stricter regulations
In a bid to thwart stricter regulation, the European pharmaceutical industry trade group pledged to…
STAT+: U.K. readies a Netflix-style subscription payment model for badly needed antibiotics
Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming…
STAT+: Pharmalittle: Will Biogen sue CMS over Alzheimer’s drug coverage? Novartis plans to lay off thousands
Hello, everyone, and how are you this morning? A spot of rain is falling on…
STAT+: FDA scolds Bausch Health for misleading claims about a psoriasis cream
The U.S. Food and Drug Administration has scolded Bausch Health for a video and webpage…
STAT+: Pharmalittle: Lilly and Eisai will still seek accelerated approval for Alzheimer’s drugs; CAR-T cells may shrink some solid tumors
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Whither accelerated approval? Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a…
.jpg)
STAT+: Pharmalittle: Medicare finalizes plan for controversial Alzheimer’s drug; advocacy group faces controversy over CMS proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Advocacy group’s advisory board members defect over Biogen Alzheimer’s drug
The furious debate over Biogen’s Alzheimer’s treatment has now sparked controversy over the Alliance for…
STAT+: Pharmalittle: Low-income Part D beneficiaries without subsidies often don’t fill scripts; Pfizer strikes a deal for RSV drugs
Hello, everyone, and how are you today? Gray skies are hovering over the chilly Pharmalot…
STAT+: Many Medicare Part D beneficiaries don’t fill prescriptions for high-priced medicines
Medicare Part D beneficiaries who have low incomes and receive government subsidies were nearly twice…
STAT+: Pharmalittle: Most Americans would get a second booster shot; FDA pulls Glaxo Covid treatment
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: STAT-Harris Poll: Most Americans would get a Covid-19 booster shot if recommended
As a Food and Drug Administration panel meets Wednesday to sort out the ongoing use…
STAT+: Colombian government faces calls to issue compulsory license for Pfizer’s Covid-19 pill
In the latest bid to expand access to the Pfizer Covid-19 pill, several advocacy groups…
STAT+: Pharmalittle: Bluebird axes nearly one-third of its employees; Senate committee probes Merck’s tax practices
Hello, everyone, and how are you today? A cloudy cover greeted us this morning, but…
STAT+: Wyden wants details on Merck’s U.S. taxes as part of expanding probe into pharma practices
The head of the U.S. Senate Finance Committee is seeking details from Merck about the…
STAT+: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible
Amid ongoing debate over biosimilar use in the United States, a new government analysis found…
STAT+: Pharmalittle: Novartis reorganizes and hopes to save $1 billion; industry-backed antibiotic fund makes first investments
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharma’s ambitious new antibiotic venture fund makes its first investments
One year after its splashy launch, the AMR Action Fund has made its first investments…
STAT+: The biotech scorecard for the second quarter: 21 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT+: Pharmalittle: Califf admits Alzheimer’s drug controversy has hurt expert trust in FDA; House passes bill to lower insulin costs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Mark Cuban’s company is building a ‘parallel supply chain’ for prescription drugs
Mark Cuban’s drug company started with an ambitious premise: to circumvent middlemen to offer cheaper…
STAT+: In the wake of Covid, a World Health Assembly proposal would bolster quality of clinical trials
Ahead of a World Health Assembly meeting in May, the United Kingdom is circulating a…
STAT+: Pharmalittle: Advisory panel narrowly votes down ALS drug; Vertex looks to advance experimental pain drug
Good morning. Elizabeth Cooney here, borrowing the virtual Pharmalittle chair while Ed Silverman takes Manhattan…
STAT+: Pharma companies face shareholder proposals to widen access to medicines, rework business plans
Over the next few weeks, several major pharmaceutical companies will face a fresh crop of…
STAT+: CVS, Teva, and Allergan reach massive deal with Florida over the opioid crisis
On the eve of a trial, the state of Florida has reached a massive settlement…
STAT+: Pharmalittle: Roche immunotherapy fails its first test; key U.S. senators move closer to bill to cap insulin prices
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Roche anti-TIGIT cancer immunotherapy fails in first late-stage clinical trial
Roche said Wednesday that an experimental cancer immunotherapy directed against a target called TIGIT failed…
STAT+: HHS seeks to penalize another drugmaker amid legal clash over drug discount program
The U.S. Health and Resources Administration is seeking to penalize Boehringer Ingelheim for curtailing discounts…
STAT+: Inflation caused ‘unprecedented’ drops in net pharmaceutical prices, analysis finds
Amid ongoing turmoil over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: Pharmalittle: Pfizer employees balk at returning overpayments; Biogen stops work on another ALS drug
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Pharmalittle: Pharma showers cash on a rising U.S. Senate star; FDA restricts use of a Glaxo Covid treatment
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pharma hunts for a cure for long Covid; Texas AG deepens puberty-blocker probe into AbbVie and Endo
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
Even as prices rose substantially in the U.S. over a recent 12-year period, a new…